
Roivant’s Q3 2024 Financial Report: A Peek into the Lab Coat-Wearing Money Maker 🔬💰
Roivant’s Q3 Update: New Indications for Brepocitinib and Updates on IMVT-1402, Batoclimab, and Legal Matters Roivant Sciences, a biopharmaceutical company known for its innovative approach to drug development, recently released its financial results for the third quarter of 2024 and shared some exciting updates on its pipeline. Let’s dive into the details. Brepocitinib in Cutaneous…